intravenous drip

THURSDAY, Nov. 3, 2016 (HealthDay News) -- Patients with melanoma treated with a combination of ipilimumab and nivolumab may be at risk for a potentially fatal T-cell-driven drug reaction, according to a report published in the Nov. 3 issue of the New England Journal of Medicine.

Douglas B. Johnson, M.D., from the Vanderbilt University Medical Center in Nashville, and colleagues report on the cases of two patients (a 65-year-old woman and a 63-year-old man) with metastatic melanoma who were treated with ipilimumab and nivolumab in clinical trials.

The researchers note that both patients developed myositis with rhabdomyolysis; exhibited early progressive and refractory cardiac electrical instability; and had T-cell and macrophage infiltrates present in myocarditis. The clonal T-cell populations that had infiltrated the myocardium were found to be identical to those seen in tumors and skeletal muscle. In pharmacovigilance studies, myocarditis was found to occur in 0.27 percent of patients treated with ipilimumab and nivolumab.

"Combined immune checkpoint inhibition with ipilimumab and nivolumab has produced frequent and durable antitumor responses in patients with advanced melanoma," the authors write. "Clinicians should be vigilant for immune-mediated myocarditis, particularly because of its early onset, nonspecific symptomatology, and fulminant progression."

Several authors disclosed financial ties to pharmaceutical companies, including Bristol-Myers Squibb, which manufactures ipilimumab and nivolumab.

Full Text (subscription or payment may be required)

Physician's Briefing

Updated on May 30, 2022

Read this Next
About UsOur ProductsCustom SolutionsHow it’s SoldOur ResultsDeliveryContact UsBlogPrivacy PolicyFAQ